PharOS MT Ltd. Pharos Pharmaceutical Oriented Services Ltd.

Poland

All drugs from this manufacturer

  • BRELUNCOL

    The medicine is used in adults, adolescents, and children from 2 years of age to reduce the number of seizures in epilepsy with partial seizures (with or without secondary generalization).

    Dosage form: tablets, film-coated

    Active substance Dosage
    brivaracetam 10 mg

    ATC: N03AX23

  • The medicine is used in adults, adolescents, and children from 2 years of age to reduce the number of seizures in epilepsy with partial seizures (with or without secondary generalization).

    Dosage form: tablets, film-coated

    Active substance Dosage
    brivaracetam 25 mg

    ATC: N03AX23

  • The medicine is used in adults, adolescents, and children from 2 years of age to reduce the number of seizures in epilepsy with partial seizures (with or without secondary generalization).

    Dosage form: tablets, film-coated

    Active substance Dosage
    brivaracetam 50 mg

    ATC: N03AX23

  • The medicine is used in adults, adolescents, and children from 2 years of age to reduce the number of seizures in epilepsy (focal seizures with or without secondary generalization).

    Dosage form: tablets, film-coated

    Active substance Dosage
    brivaracetam 75 mg

    ATC: N03AX23

  • Breluncol is an antiepileptic medicine used in adults, adolescents, and children from 2 years of age to reduce the number of seizures in epilepsy with partial seizures (with or without secondary generalization).

    Dosage form: tablets, film-coated

    Active substance Dosage
    brivaracetam 100 mg

    ATC: N03AX23

  • Kymbek is used in adults to prevent blood clots in the brain (stroke) and other blood vessels in people with atrial fibrillation and additional risk factors. It is also used to treat deep vein thrombosis in the legs and pulmonary embolism, as well as to prevent the recurrence of these clots.

    Dosage form: tablets, film-coated

    Active substance Dosage
    edoxaban 15 mg

    ATC: B01AF03

  • Kymbek is used in adults to prevent blood clots in the brain (stroke) and other blood vessels (if atrial fibrillation and additional risk factors are present) and to treat and prevent the recurrence of blood clots in the veins of the legs and pulmonary vessels.

    Dosage form: tablets, film-coated

    Active substance Dosage
    edoxaban 30 mg

    ATC: B01AF03

  • Kymbek is used in adults to prevent the formation of blood clots in the brain (stroke) and other blood vessels (in atrial fibrillation), as well as to treat deep vein thrombosis in the legs and pulmonary embolism, and to prevent their recurrence.

    Dosage form: tablets, film-coated

    Active substance Dosage
    edoxaban 60 mg

    ATC: B01AF03

  • This medicine is used to treat adults as well as children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML Ph+). It helps to stop the production of abnormal white blood cells.

    Dosage form: capsules, hard

    Active substance Dosage
    nilotinib 50 mg

    ATC: L01EA03

  • The medicine is used to treat adults as well as children and adolescents suffering from Philadelphia chromosome-positive chronic myeloid leukemia (CML Ph+). It is intended for individuals with newly diagnosed disease and for patients for whom previous treatment has not been effective or has caused severe side effects.

    Dosage form: capsules, hard

    Active substance Dosage
    nilotinib 150 mg

    ATC: L01EA03

  • The medicine is used to treat adults as well as children and adolescents suffering from Philadelphia chromosome-positive chronic myeloid leukemia (CML Ph+). It may be used in patients with newly diagnosed disease or in those for whom previous treatment has stopped working or has caused severe side effects.

    Dosage form: capsules, hard

    Active substance Dosage
    nilotinib 200 mg

    ATC: L01EA03

  • This medicine is used to treat adults, as well as children and adolescents suffering from chronic myeloid leukemia with the Philadelphia chromosome (CML Ph+). It may be used in patients with newly diagnosed disease or in patients for whom previous treatment has ceased to be effective or has caused severe side effects.

    Dosage form: capsules, hard

    Active substance Dosage
    nilotinib 150 mg

    ATC: L01EA03

  • This medicine is used to treat chronic myeloid leukemia with the Philadelphia chromosome (CML Ph+). It is intended for adults as well as children and adolescents for whom previous treatment has not been effective or has caused severe side effects.

    Dosage form: capsules, hard

    Active substance Dosage
    nilotinib 200 mg

    ATC: L01EA03

  • The medicine is used in adults to reduce the risk of blood clots. It is prescribed, among other things, in cases of acute coronary syndrome (heart attack or unstable angina) and in patients at high risk of thrombosis due to coronary artery disease or peripheral artery disease.

    Dosage form: capsules, hard

    Active substance Dosage
    rivaroxaban 2.5 mg
    acetylsalicylic acid 50 mg

    ATC: B01AF51